Nesiritide is the recombinant form of the 32 amino acid human B-type natriuretic peptide (BNP), which is normally produced by the ventricular myocardium. Human BNP binds to the particulate guanylate cyclase receptor of vascular smooth muscle and endothelial cells, leading to increased intracellular concentrations of guanosine 3'5'-cyclic monophosphate (cGMP) and smooth muscle cell relaxation. Cyclic GMP serves as a second messenger to dilate veins and arteries. Nesiritid was sold under brand name Natrecor for the intravenous treatment of patients with acutely decompensated congestive heart failure who have dyspnea at rest or with minimal activity.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2111337 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | NATRECOR Approved UseNATRECOR® is a natriuretic peptide indicated for the treatment of patients with acutely decompensated heart failure who have dyspnea at rest or with minimal activity. In this population, the use of NATRECOR® reduced pulmonary capillary wedge pressure and improved symptomatic dyspnea when measured at 3 hours of infusion Launch Date2001 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Renal subanalysis of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF): the end of nesiritide as a cardiorenal therapeutic? | 2014 Sep 16 |
|
| Dobutamine Therapy is Associated with Worse Clinical Outcomes Compared with Nesiritide Therapy for Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis. | 2015 Dec |
Sample Use Guides
The recommended dose of Natrecor (nesiritide) is an IV bolus of 2 µg/kg followed by a continuous infusion at a dose of 0.01 µg/kg/min. Natrecor should not be initiated at a dose that is above the recommended dose. Prime the IV tubing with an infusion of 25 mL prior to connecting to the patient's vascular access port and prior to administering the bolus or starting the infusion.
Route of Administration:
Intravenous
| Substance Class |
Protein
Created
by
admin
on
Edited
Sat Dec 16 00:26:07 GMT 2023
by
admin
on
Sat Dec 16 00:26:07 GMT 2023
|
| Protein Type | PEPTIDE |
| Protein Sub Type | |
| Sequence Origin | HUMAN |
| Sequence Type | COMPLETE |
| Record UNII |
P7WI8UL647
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QC01DX19
Created by
admin on Sat Dec 16 00:26:08 GMT 2023 , Edited by admin on Sat Dec 16 00:26:08 GMT 2023
|
||
|
NDF-RT |
N0000011465
Created by
admin on Sat Dec 16 00:26:08 GMT 2023 , Edited by admin on Sat Dec 16 00:26:08 GMT 2023
|
||
|
WHO-ATC |
C01DX19
Created by
admin on Sat Dec 16 00:26:07 GMT 2023 , Edited by admin on Sat Dec 16 00:26:07 GMT 2023
|
||
|
NDF-RT |
N0000175593
Created by
admin on Sat Dec 16 00:26:08 GMT 2023 , Edited by admin on Sat Dec 16 00:26:08 GMT 2023
|
||
|
NCI_THESAURUS |
C29707
Created by
admin on Sat Dec 16 00:26:08 GMT 2023 , Edited by admin on Sat Dec 16 00:26:08 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CHEMBL1201668
Created by
admin on Sat Dec 16 00:26:07 GMT 2023 , Edited by admin on Sat Dec 16 00:26:07 GMT 2023
|
PRIMARY | |||
|
C47636
Created by
admin on Sat Dec 16 00:26:08 GMT 2023 , Edited by admin on Sat Dec 16 00:26:08 GMT 2023
|
PRIMARY | |||
|
30934-4
Created by
admin on Sat Dec 16 00:26:07 GMT 2023 , Edited by admin on Sat Dec 16 00:26:07 GMT 2023
|
PRIMARY | |||
|
P7WI8UL647
Created by
admin on Sat Dec 16 00:26:07 GMT 2023 , Edited by admin on Sat Dec 16 00:26:07 GMT 2023
|
PRIMARY | |||
|
124584-08-3
Created by
admin on Sat Dec 16 00:26:07 GMT 2023 , Edited by admin on Sat Dec 16 00:26:07 GMT 2023
|
PRIMARY | |||
|
DB04899
Created by
admin on Sat Dec 16 00:26:07 GMT 2023 , Edited by admin on Sat Dec 16 00:26:07 GMT 2023
|
PRIMARY | |||
|
KK-124
Created by
admin on Sat Dec 16 00:26:08 GMT 2023 , Edited by admin on Sat Dec 16 00:26:08 GMT 2023
|
PRIMARY | |||
|
m2635
Created by
admin on Sat Dec 16 00:26:07 GMT 2023 , Edited by admin on Sat Dec 16 00:26:07 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB12539MIG
Created by
admin on Sat Dec 16 00:26:07 GMT 2023 , Edited by admin on Sat Dec 16 00:26:07 GMT 2023
|
PRIMARY | |||
|
1901
Created by
admin on Sat Dec 16 00:26:07 GMT 2023 , Edited by admin on Sat Dec 16 00:26:07 GMT 2023
|
PRIMARY | |||
|
7790
Created by
admin on Sat Dec 16 00:26:07 GMT 2023 , Edited by admin on Sat Dec 16 00:26:07 GMT 2023
|
PRIMARY | |||
|
NESIRITIDE
Created by
admin on Sat Dec 16 00:26:08 GMT 2023 , Edited by admin on Sat Dec 16 00:26:08 GMT 2023
|
PRIMARY | |||
|
19666
Created by
admin on Sat Dec 16 00:26:08 GMT 2023 , Edited by admin on Sat Dec 16 00:26:08 GMT 2023
|
PRIMARY | RxNorm | ||
|
DTXSID101026612
Created by
admin on Sat Dec 16 00:26:07 GMT 2023 , Edited by admin on Sat Dec 16 00:26:07 GMT 2023
|
PRIMARY | |||
|
4890
Created by
admin on Sat Dec 16 00:26:07 GMT 2023 , Edited by admin on Sat Dec 16 00:26:07 GMT 2023
|
PRIMARY |
| From | To |
|---|---|
| 1_10 | 1_26 |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
|
INGREDIENT -> STARTING MATERIAL |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| MOL_WEIGHT:FORMULA | CHEMICAL |
|
||||
| Molecular Formula | CHEMICAL |
|